Antiangiogenic therapy in diabetic nephropathy.
Zent
Roy
R
Pozzi
Ambra
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D001324:Autoantigens / Q000627:therapeutic use; D024141:Collagen Type IV / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D051381:Rats
D020533:Angiogenesis Inhibitors; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001324:Autoantigens; D024141:Collagen Type IV; C057112:type IV collagen alpha3 chain; D043168:Angiostatins